Selected research
Industry Research
Nano Antibodies Industry Research Report 2026
Market perspective
The global Nano Antibodies market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Nano Antibodies market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Nano Antibodies market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Nano Antibodies market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Nano Antibodies include Absolute Antibody, Alpalife (Shenzhen kangti Co., Ltd.), Alphamab Oncology, Beroni Group, ChromoTek GmbH, Cusabio Technology LLC., DiosCURE Therapeutics SE, ExeVir Bio BV and Genscript, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Nano Antibodies market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Nano Antibodies.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Nano Antibodies Market by Company
Absolute Antibody
Alpalife (Shenzhen kangti Co., Ltd.)
Alphamab Oncology
Beroni Group
ChromoTek GmbH
Cusabio Technology LLC.
DiosCURE Therapeutics SE
ExeVir Bio BV
Genscript
PerkinElmer Inc. (BioLegend, Inc.)
Sensei Biotherapeutics, Inc.
Taisho Pharmaceutical Holdings
Merck KGaA
Novartis AG
Thermo Fisher Scientific Inc.
Sanofi (Ablynx)
Nano Antibodies Segment by Type
Fusion Nanobody
Multivalent and multispecific Nanobodies
Monovalent Nanobody
Nano Antibodies Segment by Application
Tumor targeted therapy
Circulatory disease
Disease detection in vitro
Non-invasive diagnosis in vivo
Nervous system disease
Infectious disease
Other
Nano Antibodies Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nano Antibodies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Nano Antibodies and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nano Antibodies.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Nano Antibodies companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Fusion Nanobody
- Multivalent and multispecific Nanobodies
- Monovalent Nanobody
Applications
- Tumor targeted therapy
- Circulatory disease
- Disease detection in vitro
- Non-invasive diagnosis in vivo
- Nervous system disease
- Infectious disease
- Other
Companies covered
- Absolute Antibody
- Alpalife (Shenzhen kangti Co., Ltd.)
- Alphamab Oncology
- Beroni Group
- ChromoTek GmbH
- Cusabio Technology LLC.
- DiosCURE Therapeutics SE
- ExeVir Bio BV
- Genscript
- PerkinElmer Inc. (BioLegend, Inc.)
- Sensei Biotherapeutics, Inc.
- Taisho Pharmaceutical Holdings
- Merck KGaA
- Novartis AG
- Thermo Fisher Scientific Inc.
- Sanofi (Ablynx)
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Nano Antibodies by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Fusion Nanobody
- 2.2.3 Multivalent and multispecific Nanobodies
- 2.2.4 Monovalent Nanobody
- 2.3 Nano Antibodies by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Tumor targeted therapy
- 2.3.3 Circulatory disease
- 2.3.4 Disease detection in vitro
- 2.3.5 Non-invasive diagnosis in vivo
- 2.3.6 Nervous system disease
- 2.3.7 Infectious disease
- 2.3.8 Other
- 2.4 Assumptions and Limitations
3 Nano Antibodies Breakdown Data by Type
- 3.1 Global Nano Antibodies Historic Market Size by Type (2021-2026)
- 3.2 Global Nano Antibodies Forecasted Market Size by Type (2027-2032)
4 Nano Antibodies Breakdown Data by Application
- 4.1 Global Nano Antibodies Historic Market Size by Application (2021-2026)
- 4.2 Global Nano Antibodies Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Nano Antibodies Market Perspective (2021-2032)
- 5.2 Global Nano Antibodies Growth Trends by Region
- 5.2.1 Global Nano Antibodies Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Nano Antibodies Historic Market Size by Region (2021-2026)
- 5.2.3 Nano Antibodies Forecasted Market Size by Region (2027-2032)
- 5.3 Nano Antibodies Market Dynamics
- 5.3.1 Nano Antibodies Industry Trends
- 5.3.2 Nano Antibodies Market Drivers
- 5.3.3 Nano Antibodies Market Challenges
- 5.3.4 Nano Antibodies Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Nano Antibodies Players by Revenue
- 6.1.1 Global Top Nano Antibodies Players by Revenue (2021-2026)
- 6.1.2 Global Nano Antibodies Revenue Market Share by Players (2021-2026)
- 6.2 Global Nano Antibodies Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Nano Antibodies Head Office and Area Served
- 6.4 Global Nano Antibodies Players, Product Type & Application
- 6.5 Global Nano Antibodies Manufacturers Established Date
- 6.6 Global Nano Antibodies Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Nano Antibodies Market Size (2021-2032)
- 7.2 North America Nano Antibodies Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Nano Antibodies Market Size by Country (2021-2026)
- 7.4 North America Nano Antibodies Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Nano Antibodies Market Size (2021-2032)
- 8.2 Europe Nano Antibodies Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Nano Antibodies Market Size by Country (2021-2026)
- 8.4 Europe Nano Antibodies Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Nano Antibodies Market Size (2021-2032)
- 9.2 Asia-Pacific Nano Antibodies Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Nano Antibodies Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Nano Antibodies Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Nano Antibodies Market Size (2021-2032)
- 10.2 South America Nano Antibodies Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Nano Antibodies Market Size by Country (2021-2026)
- 10.4 South America Nano Antibodies Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Nano Antibodies Market Size (2021-2032)
- 11.2 Middle East & Africa Nano Antibodies Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Nano Antibodies Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Nano Antibodies Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Absolute Antibody
- 12.1.1 Absolute Antibody Company Information
- 12.1.2 Absolute Antibody Business Overview
- 12.1.3 Absolute Antibody Revenue in Nano Antibodies Business (2021-2026)
- 12.1.4 Absolute Antibody Nano Antibodies Product Portfolio
- 12.1.5 Absolute Antibody Recent Developments
- 12.2 Alpalife (Shenzhen kangti Co., Ltd.)
- 12.2.1 Alpalife (Shenzhen kangti Co., Ltd.) Company Information
- 12.2.2 Alpalife (Shenzhen kangti Co., Ltd.) Business Overview
- 12.2.3 Alpalife (Shenzhen kangti Co., Ltd.) Revenue in Nano Antibodies Business (2021-2026)
- 12.2.4 Alpalife (Shenzhen kangti Co., Ltd.) Nano Antibodies Product Portfolio
- 12.2.5 Alpalife (Shenzhen kangti Co., Ltd.) Recent Developments
- 12.3 Alphamab Oncology
- 12.3.1 Alphamab Oncology Company Information
- 12.3.2 Alphamab Oncology Business Overview
- 12.3.3 Alphamab Oncology Revenue in Nano Antibodies Business (2021-2026)
- 12.3.4 Alphamab Oncology Nano Antibodies Product Portfolio
- 12.3.5 Alphamab Oncology Recent Developments
- 12.4 Beroni Group
- 12.4.1 Beroni Group Company Information
- 12.4.2 Beroni Group Business Overview
- 12.4.3 Beroni Group Revenue in Nano Antibodies Business (2021-2026)
- 12.4.4 Beroni Group Nano Antibodies Product Portfolio
- 12.4.5 Beroni Group Recent Developments
- 12.5 ChromoTek GmbH
- 12.5.1 ChromoTek GmbH Company Information
- 12.5.2 ChromoTek GmbH Business Overview
- 12.5.3 ChromoTek GmbH Revenue in Nano Antibodies Business (2021-2026)
- 12.5.4 ChromoTek GmbH Nano Antibodies Product Portfolio
- 12.5.5 ChromoTek GmbH Recent Developments
- 12.6 Cusabio Technology LLC.
- 12.6.1 Cusabio Technology LLC. Company Information
- 12.6.2 Cusabio Technology LLC. Business Overview
- 12.6.3 Cusabio Technology LLC. Revenue in Nano Antibodies Business (2021-2026)
- 12.6.4 Cusabio Technology LLC. Nano Antibodies Product Portfolio
- 12.6.5 Cusabio Technology LLC. Recent Developments
- 12.7 DiosCURE Therapeutics SE
- 12.7.1 DiosCURE Therapeutics SE Company Information
- 12.7.2 DiosCURE Therapeutics SE Business Overview
- 12.7.3 DiosCURE Therapeutics SE Revenue in Nano Antibodies Business (2021-2026)
- 12.7.4 DiosCURE Therapeutics SE Nano Antibodies Product Portfolio
- 12.7.5 DiosCURE Therapeutics SE Recent Developments
- 12.8 ExeVir Bio BV
- 12.8.1 ExeVir Bio BV Company Information
- 12.8.2 ExeVir Bio BV Business Overview
- 12.8.3 ExeVir Bio BV Revenue in Nano Antibodies Business (2021-2026)
- 12.8.4 ExeVir Bio BV Nano Antibodies Product Portfolio
- 12.8.5 ExeVir Bio BV Recent Developments
- 12.9 Genscript
- 12.9.1 Genscript Company Information
- 12.9.2 Genscript Business Overview
- 12.9.3 Genscript Revenue in Nano Antibodies Business (2021-2026)
- 12.9.4 Genscript Nano Antibodies Product Portfolio
- 12.9.5 Genscript Recent Developments
- 12.10 PerkinElmer Inc. (BioLegend, Inc.)
- 12.10.1 PerkinElmer Inc. (BioLegend, Inc.) Company Information
- 12.10.2 PerkinElmer Inc. (BioLegend, Inc.) Business Overview
- 12.10.3 PerkinElmer Inc. (BioLegend, Inc.) Revenue in Nano Antibodies Business (2021-2026)
- 12.10.4 PerkinElmer Inc. (BioLegend, Inc.) Nano Antibodies Product Portfolio
- 12.10.5 PerkinElmer Inc. (BioLegend, Inc.) Recent Developments
- 12.11 Sensei Biotherapeutics, Inc.
- 12.11.1 Sensei Biotherapeutics, Inc. Company Information
- 12.11.2 Sensei Biotherapeutics, Inc. Business Overview
- 12.11.3 Sensei Biotherapeutics, Inc. Revenue in Nano Antibodies Business (2021-2026)
- 12.11.4 Sensei Biotherapeutics, Inc. Nano Antibodies Product Portfolio
- 12.11.5 Sensei Biotherapeutics, Inc. Recent Developments
- 12.12 Taisho Pharmaceutical Holdings
- 12.12.1 Taisho Pharmaceutical Holdings Company Information
- 12.12.2 Taisho Pharmaceutical Holdings Business Overview
- 12.12.3 Taisho Pharmaceutical Holdings Revenue in Nano Antibodies Business (2021-2026)
- 12.12.4 Taisho Pharmaceutical Holdings Nano Antibodies Product Portfolio
- 12.12.5 Taisho Pharmaceutical Holdings Recent Developments
- 12.13 Merck KGaA
- 12.13.1 Merck KGaA Company Information
- 12.13.2 Merck KGaA Business Overview
- 12.13.3 Merck KGaA Revenue in Nano Antibodies Business (2021-2026)
- 12.13.4 Merck KGaA Nano Antibodies Product Portfolio
- 12.13.5 Merck KGaA Recent Developments
- 12.14 Novartis AG
- 12.14.1 Novartis AG Company Information
- 12.14.2 Novartis AG Business Overview
- 12.14.3 Novartis AG Revenue in Nano Antibodies Business (2021-2026)
- 12.14.4 Novartis AG Nano Antibodies Product Portfolio
- 12.14.5 Novartis AG Recent Developments
- 12.15 Thermo Fisher Scientific Inc.
- 12.15.1 Thermo Fisher Scientific Inc. Company Information
- 12.15.2 Thermo Fisher Scientific Inc. Business Overview
- 12.15.3 Thermo Fisher Scientific Inc. Revenue in Nano Antibodies Business (2021-2026)
- 12.15.4 Thermo Fisher Scientific Inc. Nano Antibodies Product Portfolio
- 12.15.5 Thermo Fisher Scientific Inc. Recent Developments
- 12.16 Sanofi (Ablynx)
- 12.16.1 Sanofi (Ablynx) Company Information
- 12.16.2 Sanofi (Ablynx) Business Overview
- 12.16.3 Sanofi (Ablynx) Revenue in Nano Antibodies Business (2021-2026)
- 12.16.4 Sanofi (Ablynx) Nano Antibodies Product Portfolio
- 12.16.5 Sanofi (Ablynx) Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst